A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.

Clin Ophthalmol · 2018 · PMC6174300 · PMID 30323548

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Nominally significant differences were found between the active drug arms and vehicle for corneal staining scores and Schirmer’s test scores.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.